AbbVie Inc. (FRA:4AB)

Germany flag Germany · Delayed Price · Currency is EUR
195.40
+0.80 (0.41%)
At close: Oct 17, 2025
0.41%
Market Cap352.03B
Revenue (ttm)49.67B
Net Income (ttm)3.17B
Shares Outn/a
EPS (ttm)1.79
PE Ratio111.04
Forward PE19.75
Dividend5.86 (3.00%)
Ex-Dividend DateOct 15, 2025
Volume40
Average Volume146
Open192.20
Previous Close194.60
Day's Range192.20 - 195.40
52-Week Range147.00 - 209.50
Betan/a
RSI57.92
Earnings DateOct 29, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 55,000
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4AB
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

Raymond James Raises AbbVie (ABBV) Price Target to $250 | ABBV Stock News

Raymond James Raises AbbVie (ABBV) Price Target to $250 | ABBV Stock News

4 days ago - GuruFocus

AbbVie (ABBV) Advances in Depression Treatment with Bretisilocin Acquisition

AbbVie (ABBV) Advances in Depression Treatment with Bretisilocin Acquisition

4 days ago - GuruFocus

Novo taps U.S. pharma veteran from AbbVie amid drug pricing scrutiny

Novo Nordisk (NVO) stock is in focus as the company hires an executive from AbbVie (ABBV) as head of Corporate Affairs amid U.S. drug pricing scrutiny. Read more here.

4 days ago - Seeking Alpha

AbbVie (ABBV) Finalizes Acquisition of Bretisilocin, a Novel Antidepressant

AbbVie (ABBV) Finalizes Acquisition of Bretisilocin, a Novel Antidepressant

4 days ago - GuruFocus

AbbVie finishes acquisition of depression asset bretisilocin from Gilgamesh

AbbVie acquires bretisilocin, a promising phase 2 psychedelic depression treatment. Read more here.

4 days ago - Seeking Alpha

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORT...

4 days ago - PRNewsWire

AbbVie (ABBV) Faces Legal Challenge Amid Stock Recovery

AbbVie (ABBV) Faces Legal Challenge Amid Stock Recovery

5 days ago - GuruFocus

Guru Fundamental Report for ABBV

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim v...

5 days ago - Nasdaq

AbbVie's Bretisilocin Hit With Enveric IP Claim

AbbVie's Bretisilocin Hit With Enveric IP Claim

6 days ago - GuruFocus

Enveric Biosciences (ENVB) Pursues Legal Action Against AbbVie

Enveric Biosciences (ENVB) Pursues Legal Action Against AbbVie

6 days ago - GuruFocus

AbbVie could face patent battle over depression asset gained in Gilgamesh deal

Enveric Biosciences challenges AbbVie on patent rights over a depression candidate, bretisilocin. Read more here.

6 days ago - Seeking Alpha

AbbVie (ABBV) Pursues Acquisition Amid Patent Dispute Over Bretisilocin

AbbVie (ABBV) Pursues Acquisition Amid Patent Dispute Over Bretisilocin

6 days ago - GuruFocus

Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?

ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.

7 days ago - Nasdaq

JEPI, ABBV, JNJ, ROST: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the JPMorgan Equity Premium Income ETF (Symbol: JEPI) where we have detect...

7 days ago - Nasdaq

Amazon, AbbVie, Datadog And A Financial Stock: CNBC's 'Final Trades'

On CNBC's “ Halftime Report Final Trades ,” on Monday, Jim Lebenthal , partner at Cerity Partners, said AbbVie Inc (NYSE: ABBV) has gained 30% this year. The stock has a good dividend yield and also ...

7 days ago - Benzinga

If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today

AbbVie (NYSE: ABBV) has outperformed the market over the past 10 years by 2.87% on an annualized basis producing an average annual return of 15.43%. Currently, AbbVie has a market capitalization of $...

8 days ago - Benzinga

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

The Investment Committee give you their top stocks to watch for the second half.

8 days ago - CNBC Television

ClearBridge Value Strategy adds AMZN, TSM, CRM, exits INTC, ABBV, EXPE among Q3 moves

Discover how the ClearBridge Value Strategy outperformed its benchmark in Q2, key sector moves, and insights into gold and health care trends.

8 days ago - Seeking Alpha

AbbVie Gets FDA Approval To Expand RINVOQ Use For Ulcerative Colitis And Crohn's Disease

(RTTNews) - AbbVie (ABBV) Monday announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ (upadacit...

8 days ago - Nasdaq

Final Trades: Abbvie, Amazon, Datadog and Sixth Street Specialty Lending

The Investment Committee give you their top stocks to watch for the second half.

8 days ago - CNBC

FDA Expands AbbVie's Rinvoq (ABBV) Indication for Colitis and Crohn's

FDA Expands AbbVie's Rinvoq (ABBV) Indication for Colitis and Crohn's

8 days ago - GuruFocus

FDA Expands AbbVie's (ABBV) RINVOQ Approval for Ulcerative Colitis and Crohn's Disease

FDA Expands AbbVie's (ABBV) RINVOQ Approval for Ulcerative Colitis and Crohn's Disease

8 days ago - GuruFocus